A Mixed Bag For Lipocine, Inc.

Lipocine Inc (LPCN) slumped after opening sharply higher today. The stock rallied in the pre-market due to the company releasing a report detailing apparently positive indications for LPCN for its potential in the treatment of liver fat in hypogonadal males. However, biotech columnist Adam Feuerstein voiced negative comments, stating that he believes the study was not conducted properly and therefore questions the validity of the results. Here’s a recap.